Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
Our findings reveal that NOTCH3-dependent survival programs represent a shared vulnerability in both cells refractory to therapy and dormant cells. These programs can be exploited to overcome the diverse mechanisms by which cancer cells evade therapy, potentially preventing disease relapse and extending remission in patients with MM.
Authors
- Hayley M. Sabol (ORCID: https://orcid.org/0000-0003-2498-9258)
- Peter I. Croucher (ORCID: https://orcid.org/0000-0002-7102-2413)
- Carolina Schinke (ORCID: https://orcid.org/0000-0002-2699-1741)
- Aric Anloague
- Frank H. Ebetino (ORCID: https://orcid.org/0000-0002-9133-1360)
- James D. Smith
- Bethany C. Paxton
- Delgado-Calle Jesus
- Elena Ambrogini
- Sharmin Khan
- Japneet Kaur (ORCID: https://orcid.org/0009-0004-4840-0764)
- Mattie R Nester
- Cody Ashby
- Jeffrey B. Stambough
- Corey O. Montgomery
- Michelle M. McDonald
- C. Lowry Barnes
Institutions
- Pasadena City College (US)
- The University of Sydney (AU)
- Garvan Institute of Medical Research (AU)
- Central Arkansas Veterans Healthcare System (US)
- Winthrop Rockefeller Foundation (US)
- University of Rochester (US)
- University of Arkansas for Medical Sciences (US)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2026-01-04
- DOI
- https://doi.org/10.1186/s13046-025-03630-1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00